Cardiac Risk Panel

The Cardiac Risk Panel panel contains 7 tests with 17 biomarkers.

The Cardiac Risk Panel:

The Cardiac Risk Panel provides a comprehensive assessment designed to provide you with valuable insights into your cardiovascular health and potential risks.

By analyzing a range of markers, including genetic factors, inflammation indicators, lipid metabolism, and cardiac stress markers, this panel offers a personalized approach to understanding your unique cardiac risk profile.

With the information provided by the Cardiac Risk Panel, you can take proactive steps to manage your cardiovascular health, make informed lifestyle choices, and work closely with healthcare professionals to reduce your risk of cardiovascular disease.

  • CARDIO IQ™ LP PLA2 Activity: LP PLA2 (Lipoprotein-associated phospholipase A2) is an enzyme involved in the inflammatory process within blood vessels. Measuring LP PLA2 activity through the CARDIO IQ™ test can help assess the risk of plaque buildup and inflammation in the arteries, which are significant contributors to cardiovascular disease.
  • Lipoprotein (A): Lipoprotein (a) is a type of lipoprotein-associated with an increased risk of cardiovascular disease. Measuring the level of lipoprotein (a) in the blood can provide insights into your potential risk for developing heart-related conditions.
  • Methylenetetrahydrofolate Reductase (MTHFR), DNA Mutation Analysis: The MTHFR gene encodes an enzyme involved in folate metabolism. DNA mutation analysis of the MTHFR gene can identify specific variants, such as C677T and A1298C, which may impact the efficiency of the MTHFR enzyme. These variants have been associated with altered folate metabolism and potential health implications.
  • Myeloperoxidase Antibody (MPO): Myeloperoxidase is an enzyme produced by white blood cells that plays a role in the development and progression of atherosclerosis. Measuring the levels of myeloperoxidase antibodies can help assess inflammation and oxidative stress in the arteries, providing insights into cardiovascular risk.
  • Omega-3 and -6 Fatty Acids, Plasma: Omega-3 and -6 fatty acids are essential fats that play a crucial role in cardiovascular health. Measuring the levels of these fatty acids in plasma can provide insights into your dietary intake and balance of these beneficial fats, which can influence cardiovascular risk factors.
  • proBNP, N-terminal: ProBNP (N-terminal pro-brain natriuretic peptide) is a marker used to assess heart function and detect the presence of heart failure. Measuring proBNP levels can help evaluate cardiac stress and identify potential cardiac abnormalities.

The Cardiac Risk Panel offers a comprehensive evaluation of your cardiovascular health, providing you with valuable information about your genetic predispositions, inflammation markers, lipid metabolism, and cardiac stress indicators.

By understanding your unique cardiac risk profile, you can take proactive measures to mitigate potential risks and optimize your cardiovascular well-being.

Armed with this knowledge, you can make informed decisions about lifestyle modifications, collaborate closely with healthcare professionals, and embrace a proactive approach to heart health. Remember, early detection, personalized interventions, and ongoing management are key to maintaining a healthy heart and reducing the likelihood of cardiovascular disease. Take charge of your cardiovascular health today with the insights provided by the Cardiac Risk Panel.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: ApoE Genotype, ApoE Genotype Cardio IQ, Apolipoprotein E Genotype, Cardio IQ ApoE Genotype

Apoe Genotype

The test for ApoE is may be used in combination with other lipid tests that evaluate risk for CVD, such as cholesterol levels and lipoprotein electrophoresis. It may be used to check for and help to diagnose a genetic component to a lipid abnormality. Testing for ApoE may sometimes be ordered to help guide lipid treatment. In cases of high cholesterol and triglyceride levels, statins are usually considered the treatment of choice to decrease the risk of developing CVD. However, there is a wide variability in the response to these lipid-lowering drugs that is in part influenced by the Apo E genotype. Though appropriately responsive to a low fat diet, people with ApoE e4 may be less likely than those with ApoE e2 to respond to statins by decreasing their levels of LDL-C and may require adjustments to their treatment plans In Alzheimer's Disease - ApoE genotyping is also sometimes used as an adjunct test to help in the diagnosis of probable late onset Alzheimer's disease (AD) in symptomatic adults. It is called susceptibility or risk factor testing because it indicates whether there is an increased risk of AD but is not specifically diagnostic of AD. If a patient has dementia, the presence of ApoE4 may increase the likelihood that the dementia is due to AD, but does not prove that it is.

Guidance Statements

Method

Reviewer

LP PLA2 ACTIVITY

Also known as: Lipoprotein A, Lp (a), Lp(a)

Lipoprotein (A)

Lipoprotein-a, or Lp(a) are molecules made of proteins and fat. They carry cholesterol and similar substances through the blood. A high level of Lp(a) is considered a risk factor for heart disease. High levels of lipoproteins can increase the risk of heart disease. The test is done to check your risk of atherosclerosis, stroke, and heart attack.

Also known as: Methylenetetrahydrofolate Reductase MTHFR DNA Mutation Analysis, MTHFR

Methylenetetrahydrofolate

RESULT

Also known as: Anti-Myeloperoxidase, Churg-Strauss Syndrome, Crescentic Glomeruloephritis, MPO, Myeloperoxidase Antibody MPO

Myeloperoxidase Antibody

Antineutrophil cytoplasmic antibodies (ANCA) are a group of autoantibodies produced when a person's immune system mistakenly targets and attacks its own neutrophil proteins. Two of the most commonly targeted proteins are myeloperoxidase (MPO) and proteinase 3 (PR3). This results in the production of antibodies to MPO and/or PR3. The ANCA blood test detects the presence or absence of these autoantibodies. Antineutrophil cytoplasmic antibodies may be present in a variety of autoimmune disorders that cause inflammation and damage to blood vessels throughout the body (systemic vasculitis). Vasculitis can cause tissue and organ damage due to the narrowing and obstruction of blood vessels and the subsequent loss of blood supply. It can also produce areas of weakness in blood vessel walls, known as aneurysms, which have the potential to rupture.

Also known as: Arachidonic Acid (AA), Arachidonic Acid/EPA Ratio, DHA, EPA, Omega-3 Index, Omega-6/omega-3 Ratio, Omega3 and 6 Fatty Acids Plasma, Phospholipid Omega-3 Fatty Acid, Phospholipid Omega-6 Fatty Acid, Polyunsaturated Fatty Acids (PUFAs)

ARACHIDONIC ACID

Arachidonic acid is a polyunsaturated fatty acid present in the phospholipids (especially phosphatidylethanolamine, phosphatidylcholine, and phosphatidylinositides) of membranes of the body's cells, and is abundant in the brain, muscles, and liver. In addition to being involved in cellular signaling as a lipid second messenger involved in the regulation of signaling enzymes, such as PLC-γ, PLC-δ, and PKC-α, -β, and -γ isoforms, arachidonic acid is a key inflammatory intermediate and can also act as a vasodilator

ARACHIDONIC ACID/EPA

Arachidonic acid is a polyunsaturated fatty acid present in the phospholipids (especially phosphatidylethanolamine, phosphatidylcholine, and phosphatidylinositides) of membranes of the body's cells, and is abundant in the brain, muscles, and liver. In addition to being involved in cellular signaling as a lipid second messenger involved in the regulation of signaling enzymes, such as PLC-γ, PLC-δ, and PKC-α, -β, and -γ isoforms, arachidonic acid is a key inflammatory intermediate and can also act as a vasodilator

DHA

The omega-3 fatty acids EPA and DHA are found in seafood, such as fatty fish (e.g., salmon, tuna, and trout) and shellfish (e.g., crab, mussels, and oysters).

EPA

The omega-3 fatty acids EPA and DHA are found in seafood, such as fatty fish (e.g., salmon, tuna, and trout) and shellfish (e.g., crab, mussels, and oysters).

OMEGA 3 (EPA+DHA) INDEX

Omega-3 (n-3 polyunsaturated) fatty acids are essential fats that your body needs to function properly but does not make. Humans must eat them through food, which means getting EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from seafood, such as salmon, tuna, sardines, mackerel or shellfish, and ALA (alpha-linolenic acid) from sources such as walnuts, flaxseed, and canola and soybean oils. Omega-3 fatty acids, particularly EPA and DHA, have been shown to benefit the heart of healthy people, and those at high risk for — or who already have — cardiovascular disease.

OMEGA 6/OMEGA 3 RATIO

Omega-6 (n-6 polyunsaturated) fatty acids are the other group of essential fats that your body needs to function properly but does not make. Hence, they need to be consumed in the diet. Food sources of omega-6 fatty acids include some vegetable oils (soybean, safflower, sunflower or corn oils), nuts and seeds. Increased consumption of omega-6 fatty acids in place of saturated fats and trans fats is associated with a decreased risk of coronary heart disease.

RISK

Also known as: BNP, N-terminal pro b-type natriuretic peptide, proBNP Nterminal

Probnp, N Terminal

N-terminal pro b-type natriuretic peptide (NT-proBNP) used to detect and evaluate heart failure. BNP is actually produced primarily by the left ventricle of the heart (the heart's main pumping chamber). It is associated with blood volume and pressure and with the work that the heart must do in pumping blood throughout the body.When the left ventricle of the heart is stretched, the concentrations of NT-proBNP produced can increase markedly. This situation indicates that the heart is working harder and having more trouble meeting the body's demands. This may occur with heart failure as well as with other diseases that affect the heart and circulatory system. It does not mean that the heart has stopped working; it just means that it is not pumping blood as effectively as it should be. NT-proBNP concentrations will reflect this diminished capacity.
*Process times are an estimate and are not guaranteed. The lab may need additional time due to weather, holidays, confirmation/repeat testing, or equipment maintenance.

Customer Reviews